Dive Brief:

The country’s largest hospital lobby is accusing five major drugmakers of secretly conspiring to transition to a rebate model in 340B, in the latest salvo between providers and pharmaceutical companies over the future of the drug discount program.

On Monday, the American Hospital Association sent a letter to the heads of the Federal Trade Commission and the Justice Department’s antitrust division asking them to investigate Johnson & Johnson, Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis for potential collusion.

The AHA’s letter points to the overlapping timeline of the drugmakers’ building up to and then announcing their 340B rebate plans, all of which occurred over the same five months.

Dive Insight:

Johnson & Johnson got the ball rolling last summer when it me

See Full Page